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The article in question (1) puts into
discussion the relevance of the clinical research
carried out by the multinational pharmaceutical
industry in Latin America. I share the ethical
qualms and the profound concern over the
powerlessness of our patients, professionals,
institutions and control mechanisms when
facing the development of projects with
commercial interests (2). There is no doubt that
the best response is the consolidation of ethics
committees independent from the pharma-
ceutical industry, with an institutional base and
with members trained in clinical and bioethical
research. Currently, in the province of Buenos
Aires, the recategorization of bioethics
committees is being undertaken with great
effort, outlining the necessary skills and level of
training as well as the conditions necessary for
protocol assessment to take into account the
scientific interest of the protocol and the
protection of patients’ rights (3). Similar efforts
have been undertaken in the province of
Cordoba with good results (4). 
One of the main weaknesses preventing
an adequate analysis is the lack of training or of
previous participation in clinical trials, as well as
lack of instruction in clinical research in
undergraduate and graduate courses. 
The invasion of multicentric research
studies funded by the industry in Latin American
countries has had multiple effects on various
levels. As the authors highlight, we should not
believe that all they offer is virtuous and
beneficial, as the official rhetoric of its promoters
asserts. But I am afraid that it would be a mistake
of equally negative consequences to assume that
all is fraud, corruption and manipulation in
multicentric clinical research.
I shall provide some information that
may contribute to the debate in this sense. 
A brief history of recent clinical research
Clinical research and controlled trials,
from their initial implementation in the European
postwar period in a study organized by Bradford
Hill to test streptomycin in patients with
tuberculosis and funded by the British Medical
Research Council (5), have permitted an
extraordinary growth of solid scientific proof with
which to evaluate the benefits and risks of
pharmacological and non-pharmacological
therapeutic interventions. Evidence-based
medicine (EBM) is unthinkable without reliable
scientific proof of the usefulness of interventions.
Even though EBM may be criticized from
different perspectives and with good reason, a
medicine that is not based in scientific proofs or
that ignores them is no alternative.
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In the field of cardiology, it is illustrative
to recall that, in 1975, the treatment of heart
attacks during the first hours and throughout its
progress was prolonged rest.  Mortality during
hospitalization was 12-15% and in the first year
5% of the patients died; the percentage was even
greater in higher-risk groups. Currently, we have
interventions that reduce in-hospital mortality by
half and long term mortality by 80%, thus
extending patients’ lives by 10 to 12 years (6).
Implementation of thrombolitics, primary
angioplasty, aspirin, beta blockers, angiotensin-
converting enzyme inhibitors, statins, anti-
aldosterone treatment in the event of cardiac
insufficiency, among other interventions, have
arisen from large scale, multi-centered controlled
trials, often with Latin American participants. The
first trials were promoted by non-profit
collaborative networks such as the Gruppo
Italiano per lo Studio della Sopravvivenza
nell'Infarto miocardico (GISSI) directed by the
Mario Negri Institute of Milan and the ISIS group
of Oxford University, following in the footsteps
of Bradford Hill, with very limited support from
the pharmaceutical industry. This model of large-
scale multi-centered studies was later taken up by
the industry as the principal way of introducing
new drugs to the specialty of cardiology,
generating the immense corporate complex of
current clinical research. Cardiovascular
mortality in Argentina has been decreasing in the
last decades, and we can hypothesize that part of
this improvement is due to the medications or
interventions mentioned above (7). 
The same could be said regarding other
areas of cardiology such as cardiac insufficiency or
primary prevention in high-risk groups, as well as
regarding other pathologies with high mortality. 
As a product of the expansion of useful
treatments in cardiovascular pathologies, it is
extremely difficult to introduce new drugs that
considerably reduce morbility and mortality. This
has led to the proliferation of me-too studies,
trials with an ethical limit of non-inferiority, and
to the selection of efficacy criteria that are not
based in mortality, which are in many cases
disputable or controversial (8). This strengthens
the idea expressed by the authors of evaluating
each individual proposal in terms of its relevance
to potential findings beneficial to the community.   
ethic and clinical research education
before multi-centered trials in Argentina:
A personal confession
In his best-known work (9) Lefanu
comments on the total freedom and paternalism
with which drug research was conducted in
patients with different pathologies in university
hospitals immediately after the war, from which
came most of the pharmacological groups
currently acknowledged as valued therapeutics.
This research was carried out paying scarce
attention to the standards already existing as
regulatory guidelines. The same situation
persisted in Argentina until the start of multi-
centered trials in the second half of the 1980s. As
an intern at the Hospital Italiano de Buenos Aires
and then Head of the Coronary Unit of the
Hospital Argerich, I took part in multiple studies
based on the ideas of the medical groups
conducting them, totally ignorant of the need for
informed consent, ethics committees, or anything
of the kind. In Argentina, it was also uncommon
to request informed consent for interventions or
diagnostic procedures, as the medical practice
remained sheltered from the lawsuit industry. At
the beginning of the 1990s, I held the position
that in Argentina we should avoid requesting the
signature of patients and relatives to include them
in protocols regarding acute pathologies, which
of course inspired horror in the organizers of
multi-centered trials and would have not been
accepted by the Food and drug Administration
(FdA). At that time, there were neither reliable
nor adequately trained regulatory authorities; the
protocols were presented locally and if after 90
days there had been no response, the study was
conducted. The authorization often came
through after the trial ended.
I would like to provide an explanation
of the position I held at the time, which is now
amusingly outdated and almost anti-
humanitarian. In those days, we were completely
isolated from the malpractice lawsuit industry,
and trust was still maintained in the paternalist
medical institution. In our hospitals and clinics
the practice of asking for signatures to authorize
procedures did not exist. Relatives were only
asked to sign if an intervention was to be
performed on critical patients with unknown
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results. I remember receiving a desperate call
from one of my aunts, who told me that they
would not operate on her husband’s hip fracture
if she did not sign, because he had a history of
severe coronaropathy. “They are asking me to
sign” was a synonym for doubt that he could
survive the surgery. In the context of a patient
suffering from precordial pain and the decision to
compare thrombolytics, for example, reading a
three-page consent form and assessing its content
was absolutely impossible. Therefore, in my
opinion, if the physician briefly explained the
essence of the protocol to the patient before a
witness, verbal consent was sufficient. 
We did not get paid for the studies at that
times and I truly did not imagine that someone
would try to lie in this context. It seemed cruel and
artificial to ask for a signature, which also arose
from the confidence in the physician's word in a
difficult situation. At that time, a journal editorial
used the phrase "ethical imperialism" to refer to
the imposition of American standards on the
medical practice of other countries with different
medical cultures (10).
The dynamics of the multi-centered trials
led to the creation and training of regulatory
authorities, as well as the gradual creation of
private and hospital ethics committees. Research
regulation did not arise from the demands of
ethicists, but rather from the collateral effect of the
need for the validation of local authorities in order
to develop international multi-centered studies. 
Multi-centered studies with local ideas 
and voluntary networks
We started to overcome our lack of
training and experience in clinical research with
new local projects, at least in cardiology: the
Multi-centered Study of Streptokinase in the South
American Republics (EMERAS, from the Spanish
Estudio Multicéntrico Estreptoquinasa Repúblicas
de América del Sur) (11), the Study Group of
Survival in Cardiac Insufficiency in Argentina
(GESICA, from the Spanish Grupo de Estudio de la
Sobrevida en la Insuficiencia Cardíaca en
Argentina) (12), Enalapril in Unstable Angina: A
Multi-Centered Study (ENAI, from the Spanish
Enalapril en angina inestable) (13,14), the
GEMICA study (from the Spanish Grupo de
Estudios Multicéntricos de Infartos con
Amiodarona) (15), among others, included
thousands of patients in non-profit trials, motivated
by the requests of physicians and with little
support from the industry. These studies were
conducted in the 1990s according to the customs
of the time and perhaps would not comply with
the ethical requirements we currently demand, but
they resulted in the creation of a small critic mass
of physicians trained in clinical research.
Nevertheless, we still lack adequate structures for
the training and economic support needed for
independent research. 
The authors remark that the industry is
not interested in pathologies that, due to their
prevalence or distribution, will not provide
benefits to the industry. But what is worse, we
must acknowledge, is that the State and the
community are not interested in them either,
because they have not yet been addressed with
the seriousness and the structure they require. 
I believe that the current challenge, in
order to establish clinical research that meets the
needs of our patients, in collaboration with
universal scientific developments and with the
highest academic standards, requires the
achievement of several objectives:
1) The consolidation of ethics committees
independent from the pharmaceutical
industry, preferably linked to the university
and academic care facilities, conformed by
physicians trained in clinical research,
bioethicists and members of the community.
These committees would necessary receive
payment due to the complexity of the tasks of
supervision of adverse effects, protocol
modifications, amendments.
2) The development of public settings of bioethical
debate in which the conceptual guidelines for
difficult decisions can be discussed. I think for
example of myocardial infarction, perhaps the
most studied pathology in controlled trials, and
for which study results have had the greatest
impact in decreasing mortality. I have heard
and read the opinions of bioethicists about the
lack of ethics in researching patients with
severe pathologies (difficulty in respecting the
principle of autonomy, etc.); if such opinions
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had prevailed, today we would have thousands
more deaths per year only in Argentina, deaths
that were avoided with the results of these
trials. This is a complex dilemma whose
solution must not be lack of research. 
3) The creation of new courses and master's
degree programs in clinical research, with
practical experiences in existing projects and
objectives related to public health, in order to
reach the critical mass that will allow us to
address health problems with competence and
scientific fundaments. 
4) To establish work hours and positions dedicated
to research in public hospitals and academic
institutions. This objective necessary implies
that part of public funding for research be
directed towards clinical research. 
An epilogue on new drugs to escape 
the paradox
In one paragraph the authors highlight
the suggestion made by another author to readers
and future users to wait seven years before taking
a recently patented drug, with the aim of
accumulating experiences about its safety. The
authors then rightly state that that if this suggestion
were implemented no experience would be
accumulated and, thus, new drugs would simply
not exist. To escape this paradox that refers us to
Achilles and the tortoise, I send a decalogue for the
introduction of new drugs in chronic pathologies
for which drugs already exist (16). This decalogue
attempts to contemplate the real context in which
this problem occurs and the precautions we can
take into account in its inclusion.
Decalogue for the prescription of new drugs
for chronic use
1) due to the complex network of interests involved,
new drugs should be regarding with a critical eye.
Blind trust in the FdA, the European Medicines
Agency (EMA), the National Administration of
drugs, Food and Medical Technology (ANMAT,
from the Spanish Administración Nacional de
Medicamentos, Alimentos y Tecnología Médica),
medical sales representatives, experts and the
agreements should be avoided.
2) It is probable that only ineffective drugs or interven-
tions will be innocuous. All active drugs interfere
with a number of biological mechanisms of which
we are only familiar with a part, sometimes a minor
part. We should remember that the word phárma-
kon in Greek means both medicine and poison. 
3) The chain of events arising from the prescription of a
drug is so important that any decision about it must
be considered carefully and responsibly.
4) due to the particular condition of chronic
pathologies, it is advisable to prescribe drugs only
when non-pharmacological measures were unable
to resolve the medical issue. This suggestion is
applicable to any medical field, and especially to
psycho-affective problems.
5) drug selection should be based on pragmatic trials
when they are available.
a) Prescription on the basis of the drug action
mechanisms should be limited to patients with rare
pathologies not solved by other interventions.
b) For common pathologies, a drug whose main effect
is a new physio-pathological mechanism should
not be considered revolutionary until such a time
as there is information available from “pragmatic”
clinical trials; that is to say, until it is shown that
they have improved essential aspects of the disease
such as quality of life and survival rates.
6) The inclusion of a new drug in place of an effective
“old” drug should not be guided by any criteria
other the welfare of the patient.
a) The availability of free samples, dependency on
medical sales representatives or the industry, and
interest in demonstrating to the patient that new
drugs are used should not be logical criteria for
choosing new drugs.
b) It is only worth testing a new drug when the
available therapies are not able to control the
problem or do so at the expense of unacceptable
collateral effects. Even if an unforeseen risk is
discovered with a new drug years after its
implementation, this risk will have been
assumed in benefit of the patient, as an attempt
to alleviate an illness that could not be
controlled in another better way. If the
prescription of the new drug was due to arbitrary
criteria or because the drug was “in fashion,” this
risk would be deemed unacceptable.
7) A contribution should only be considered
revolutionary when the drug in a pragmatic trial solves
a problem for which there is no alternative strategy.
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When a historical alternative already exists, it is
preferable to wait for a direct comparison, given that
indirect comparisons in several opportunities have not
been confirmed after the relevant comparative trials
have been performed.
8) It is not advisable to suspend the administration of
drugs with known capacity to extend life and
prevent serious medical events when there is a slight
suspicion of minor collateral effects. “Not every
cough comes from ACE inhibitors and not all sexual
dysfunction comes from beta blockers.”
9) The conscious use of placebos may be a powerful
evidence-based weapon.
10) It should not be considered ethical to be rewarded
by the industry for prescribing a drug.
